GSK (GSK) plc announced that it has completed the acquisition of IDRx, Inc., a Boston-based, clinical-stage biopharmaceutical company dedicated ...

GSK plc has completed its previously announced acquisition of IDRx Inc., a Boston-based, clinical-stage biopharmaceutical ...

GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.

GSK has announced a definitive agreement to acquire IDRx, a US-based biotechnology company specialising in treatments for gastrointestinal cancers, for up to $1.15bn in cash, marking the first ...

GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy for a form of rare gastrointestinal stromal tumour (GIST). The rumoured ...

IDRx's lead molecule, IDRX-42, is an investigational tyrosine kinase inhibitor (TKI) targeting all clinically relevant primary and secondary KIT mutations in GIST. GIST is the most common form of ...

Two recent high-profile acquisitions exemplify this trend; Eli Lilly’s pursuit of Scorpion Therapeutics and GSK’s acquisition of IDRx. Eli Lilly’s Bold Bid to Lead Oncology Eli Lilly’s ...

GSK on Monday also said it has start the GBP2 billion buyback programme that it announced earlier this month, starting with an initial GBP700 million tranche.

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, ...

Today, GSK plc (LSE/NYSE: LON:GSK), a prominent pharmaceutical company with a market capitalization of $74.88 billion and impressive gross profit margins of 71.81%, announced the completion of its ...